Scientists discover kill-switch controls immune-suppressing cells

Scientists have uncovered the mechanism that controls whether cells that are able to suppress immune responses live or die. The discovery of the cell death processes that determine the number of ‘regulatory T cells’ an individual has could one day lead to better treatments for immune disorders. Regulatory T cells are members of a group » Continue Reading.

Experimental melanoma vaccine may represent future of cancer treatment

An experimental vaccine technique using a patient’s own cells to enhance the body’s immune response may represent the future of cancer treatment. In a pair of studies, researchers leveraged dendritic immune system cells found in the skin to boost immune response to melanoma in patients. Investigators from the Washington University School of Medicine in St. » Continue Reading.

Inaugural issue of American Association for Cancer Research journal Cancer Immunology Research debuts

Cancer Immunology Research, the newest publication of the American Association for Cancer Research (AACR), published its debut issue today. The journal will publish research articles reporting major advances in all areas of cancer immunology, including basic investigations in host–tumor interactions, developmental therapeutics in model systems, early translational studies in patients, and late-stage clinical trials. As » Continue Reading.

Cancer immunotherapies promise to be a new tool in fight against cancer

Drugs that direct a cancer patient’s immune system to eradicate her or his disease, known as cancer immunotherapies, promise to be a new tool in the fight against cancer. Since the Koch Institute’s inception, exploring the close relationship between the immune system and cancer has been one of the Institute’s priority research areas. The recent » Continue Reading.

Ludwig presents advancements in immunotherapy and epigenetics at the American Association for Cancer Research Annual Meeting

A dozen Ludwig scientists from around the world presented the latest advancements in basic and clinical cancer research at this week’s American Association for Cancer Research (AACR) Annual Meeting 2013. Progress in immunotherapy and epigenetics led the program with important diagnostic and treatment implications for emerging cancer therapy. “With new immunotherapy agents available to help » Continue Reading.

Immune system versus cancer

Engineering the immune system to overcome tumor evasion strategies was a hot topic at this week’s AACR meeting, with researchers discussing several new approaches. Immunotherapy has emerged as a promising way to tackle cancer over the last few years, and researchers at this year’s American Association for Cancer Research (AACR) meeting in Washington, DC, reported » Continue Reading.

Immunotherapy boosts response in recurrent ovarian cancer

A novel ovarian cancer treatment that uses the patient’s own tumor to stimulate her immune system provoked a positive response in 66% of women with advanced stage disease – including 20 patients who had no obvious disease at the end of treatment, and one who is still in complete remission nearly 4 years later. When » Continue Reading.

Novel two-step immunotherapy showed promise for patients with recurrent ovarian cancer

A novel two-step immunotherapy approach yielded clinically beneficial responses in patients with advanced ovarian cancer, including one patient who achieved complete remission, according to data from two phase I clinical trials presented at the AACR Annual Meeting 2013, held in Washington, D.C., April 6-10. “This immunotherapeutic strategy has two steps — dendritic cell vaccination and » Continue Reading.

T cells engineered to attack B cells sent adults’ acute leukemia into remission

Gene therapy has rid three adult patients of acute leukemia. The patients have been cancer-free for 5 months to 2 years, according to a study published last week (March 20) in Science Translational Medicine. Two other patients received the therapy, but one died for reasons believed to be unrelated, and the second died after relapsing. » Continue Reading.

Novel Amgen virus-vaccine shrinks melanoma tumors

Shares of drugmaker Amgen Inc. climbed Wednesday on news that its innovative melanoma drug, which uses a virus as a Trojan horse to infiltrate and destroy tumors, shrank far more tumors than a standard treatment in a late-stage test. The partial study results, released late Tuesday, show promise for similar vaccines other companies are developing. » Continue Reading.